They received the final approval for Pramipexole Dihydrochloride tablets from the USFDA. Glenmark Generics entered into an exclusive licensing agreement with Par Pharmaceuticals, USA to market ...

The manufacturer was involved in a large-scale recall event earlier this year—now a new issue with a specific prescription ...

Telangana DCA seizes counterfeit versions of Rosuvas F 20 & Rosuvas F 10 from distributors in Hyderabad: Peethaambaran Kunnathoor, Chennai Saturday, June 21, 2025, 08:00 Hrs [IST] ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 13, 2025 /EINPresswire.com/ -- There has been a significant expansion in the cyclosporine drugs market size in recent years. The detailed analysis suggests ...

Hypertension, also known as high blood pressure, is a growing health concern in the U.S. Around 50% of American adults are affected by it, according to health experts, and it’s estimated that only one ...

Sildenafil Drug Global Market Report 2025. The Business Research Company's Sildenafil Drug Global Market Report 2025 – Market Size, Trends, And Global Fo ...

Glenmark shares on Monday ended 0.68% up at ₹1,600.85 apiece on BSE. New Delhi: Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following ...

Glenmark Pharmaceuticals is preparing to launch Zanubrutinib, a cancer medicine, in India under the brand name ‘Brukinsa’after receiving the approval from the Drugs Controller General of India ...

Glenmark Pharmaceuticals is in talks with global drugmakers for a licensing deal on its ISB 2001 drug candidate being developed for use in the treatment of multiple myeloma, top executives with ...

Nomura India has released a report maintaining a 'Neutral' rating on Glenmark Pharmaceuticals Ltd, setting a target price of Rs 1,500 by September 2025. The valuation is grounded on a sum-of-the ...